Shots:

• The approval is based on two clinical studies results assessing Akynzeo (NEPA) vs Palonosetron in patients with CINV across 80 centers in 11 countries
• The two clinical studies Trial 1 (NCT#02557035) & Trial 2 (NCT # 02517021) indicated benefits & side effect of Akynzeo in 440 & 404 patients respectively
• Akynzeo is a combination of (fosnetupitant 235mg- a P/neurokinin-1 (NK-1) receptor antagonists- & palonosetron 0.25mg- a serotonin-3 (5-HT3) receptor antagonist)- IV) used in combination with dexamethasone to prevent acute and delayed nausea & vomiting occurred during repetitive course of CT

Ref: Helsinn | Image: Twitter